白细胞介素-37与心血管疾病的研究进展

doi:10.16138/j.1673-6087.2023.03.018

摘要/Abstract

中图分类号:

苏征佳, 项晓刚, 梁璆荔, 梁伟, 吴立群. 白细胞介素-37与心血管疾病的研究进展[J]. 内科理论与实践, 2023, 18(03): 221-224.

SU Zhengjia, XIANG Xiaogang, LIANG Qiuli, et al . Research progress of interleukin⁃37 effect on cardiovascular diseases[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 221-224.

参考文献 30

[1]	Rafiei A, Ahmadi R, Kazemian S, et al. Serum levels of IL-37 and correlation with inflammatory cytokines and clinical outcomes in patients with coronary artery disease[J]. J Investig Med, 2022, 70(8): 1720-1727. doi: 10.1136/jim-2021-002134 URL
[2]	Jia C, Zhuge Y, Zhang S, et al. IL-37b alleviates endothelial cell apoptosis and inflammation in Kawasaki disease through IL-1R8 pathway[J]. Cell Death Dis, 2021, 12(6): 575. doi: 10.1038/s41419-021-03852-z pmid: 34083516
[3]	Nold-Petry CA, Nold MF. Rationale for IL-37 as a novel therapeutic agent in inflammation[J]. Expert Rev Clin Immunol, 2022, 18(12): 1203-1206. doi: 10.1080/1744666X.2022.2108792 URL
[4]	Qin YF, Ren SH, Shao B, et al. The intellectual base and research fronts of IL-37: a bibliometric review of the literature from WoSCC[J]. Front Immunol, 2022, 13: 931783. doi: 10.3389/fimmu.2022.931783 URL
[5]	Yang Z, Kang L, Wang Y, et al. Role of IL-37 in cardiovascular disease inflammation[J]. Can J Cardiol, 2019, 35(7): 923-930. doi: S0828-282X(19)30268-5 pmid: 31292092
[6]	Su Z, Tao X. Current understanding of IL-37 in human health and disease[J]. Front Immunol, 2021, 12: 696605. doi: 10.3389/fimmu.2021.696605 URL
[7]	Zhuang X, Wu B, Li J, et al. The emerging role of interleukin-37 in cardiovascular diseases[J]. Immun Inflamm Dis, 2017, 5(3): 373-379. doi: 10.1002/iid3.159 URL
[8]	Lotfy H, Moaaz M, Moaaz M. The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis[J]. Vascular, 2020, 28(5): 629-642. doi: 10.1177/1708538120921735 pmid: 32366176
[9]	陈少源, 方红城, 黄于朗, 等. 白细胞介素37/Smad3在兔腹主动脉粥样硬化斑块中的表达研究[J]. 中国心血管杂志, 2019, 24(2): 161-165.
[10]	朱静和, 钱雷, 蒋凤, 等. 白细胞介素37对动脉粥样硬化患者单核巨噬细胞脂蛋白相关磷脂酶A2的抑制作用[J]. 中华老年心脑血管病杂志, 2020, 22(8): 873-875.
[11]	Liu J, Lin J, He S, et al. Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability[J]. Cell Physiol Biochem, 2018, 45(3): 1034-1050. doi: 10.1159/000487344 pmid: 29439249
[12]	Liu K, Tang Q, Zhu X, et al. IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction[J]. Clin Chim Acta, 2017, 468: 140-144. doi: S0009-8981(17)30069-4 pmid: 28237549
[13]	Liu C, Cui Y, Zhang D, et al. Analysis of serum interleukin-37 level and prognosis in patients with ACS[J]. Comput Math Methods Med, 2021, 2021:3755458.
[14]	McCurdy S, Yap J, Irei J, et al. IL-37-a putative therapeutic agent in cardiovascular diseases[J]. QJM, 2022, 115(11): 719-725. doi: 10.1093/qjmed/hcab011 URL
[15]	Yang T, Fang F, Chen Y, et al. Elevated plasma interleukin-37 playing an important role in acute coronary syndrome through suppression of ROCK activation[J]. Oncotarget, 2017, 8(6): 9686-9695. doi: 10.18632/oncotarget.14195 pmid: 28039466
[16]	Li X, Hu H, Guo D, et al. Imbalance of pro- and anti-inflammatory cytokines induced different types of recurrent atrial arrhythmias after drug eluting coronary stent implantation[J]. Curr Vasc Pharmacol, 2022, 20(5): 447-456. doi: 10.2174/1570161120666220831094507 pmid: 36045517
[17]	Mao X, Zhu R, Zhang F, et al. IL-37 plays a beneficial role in patients with acute coronary syndrome[J]. Mediators Inflamm, 2019, 2019: 9515346.
[18]	Zhu R, Zhang F, Pan C, et al. Role of IL-37- and IL-37-treated dendritic cells in acute coronary syndrome[J]. Oxid Med Cell Longev, 2021, 2021: 6454177.
[19]	Shou X, Lin J, Xie C, et al. Plasma IL-37 elevated in patients with chronic heart failure and predicted major adverse cardiac events[J]. Dis Markers, 2017, 2017: 9134079.
[20]	曲延成, 杨赞. 慢性心力衰竭患者心功能与血浆IL-18、IL-37及IL-33的相关性研究[J]. 贵州医药, 2018, 42(6): 659-661.
[21]	王毅, 陈海潮, 林静, 等. 慢性心力衰竭患者血浆白介素-37水平变化研究[J]. 临床医学研究与实践, 2019, 4(5): 93-95.
[22]	de Sanctis JB. Innate immune response in hypertension[J]. Curr Pharm Des, 2022, 28(36): 2984-2990. doi: 10.2174/1381612828666220922112412 URL
[23]	Ye J, Wang Y, Wang Z, et al. Circulating IL-37 levels are elevated in patients with hypertension[J]. Exp Ther Med, 2021, 21(6): 558. doi: 10.3892/etm.2021.9990 pmid: 33850530
[24]	胡耀明, 雷慧娟. IL-6、IL-18与心房颤动的关系研究[J]. 实用中西医结合临床, 2019, 19(8): 1-2.
[25]	Li W, Li S, Li X, et al. Interleukin-37 elevation in patients with atrial fibrillation[J]. Clin Cardiol, 2017, 40(2): 66-72. doi: 10.1002/clc.22630 pmid: 28244597
[26]	Li J, Zhang WJ, Yao H, et al. Therapeutic effects of interleukin-37 and induced cardiosphere on treating myocardial ischemia-reperfusion injury[J]. Int Immunopharmacol, 2020, 88:106719. doi: 10.1016/j.intimp.2020.106719 URL
[27]	Wang YM, Zhang JJ, Wu BW, et al. IL-37 improves mice myocardial infarction via inhibiting YAP-NLRP3 signaling mediated macrophage programming[J]. Eur J Pharmacol, 2022, 934:175293. doi: 10.1016/j.ejphar.2022.175293 URL
[28]	López-Bautista F, Posadas-Sánchez R, Vázquez-Vázquez C, et al. IL-37 gene and cholesterol metabolism: association of polymorphisms with the presence of hypercholesterolemia and cardiovascular risk factors[J]. Biomolecules, 2020, 10(10): 1409. doi: 10.3390/biom10101409 URL
[29]	López-Bautista F, Posadas-Sánchez R, Vargas-Alarcón G. Association of the IL-37 polymorphisms with transaminases and alkaline phosphatase levels in premature coronary artery disease patients and healthy controls[J]. Diagnostics (Basel), 2021, 11(6): 1018.
[30]	Yin D, Naji DH, Xia Y, et al. Genomic variant in IL-37 confers a significant risk of coronary artery disease[J]. Sci Rep, 2017, 7: 42175. doi: 10.1038/srep42175 pmid: 28181534

白细胞介素-37与心血管疾病的研究进展

Research progress of interleukin⁃37 effect on cardiovascular diseases

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	尚思雨, 相阳, 潘博涵. 褐藻寡糖对创面的生物学效应：裂解程度依赖性 [J]. 组织工程与重建外科杂志, 2023, 19(1): 1-.
[2]	李士杰　姜爱莉　刘宇　王召旭　韩倩倩. 巨噬细胞介导的炎症反应在材料生物相容性评价中的意义[J]. 组织工程与重建外科杂志, 2022, 18(5): 436-.
[3]	陈英, 张晨莉, 姚玮艳. 粒细胞和单核细胞吸附分离治疗中-重度炎症性肠病的有效性及安全性分析[J]. 内科理论与实践, 2022, 17(06): 441-446.
[4]	陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰. 心血管转化研究的若干进展[J]. 内科理论与实践, 2022, 17(05): 369-372.
[5]	刘锐锋, 盛倩倩, 张悦, 赵慧强. 冠状动脉扩张患者淋巴细胞和单核细胞亚型分析[J]. 内科理论与实践, 2022, 17(05): 373-378.
[6]	闫晓红, 薄建萍. 呼出气一氧化氮在下气道慢性炎症疾病中的评估价值[J]. 内科理论与实践, 2022, 17(05): 418-422.
[7]	刘萍, 肖园, 王歆琼, 陆亭伟, 赵雪松, 杨媛艳. Wiskott-Aldrich综合征合并克罗恩病一例并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 349-354.
[8]	戴生明. 银屑病关节炎的诊治现状与挑战[J]. 内科理论与实践, 2022, 17(03): 186-189.
[9]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦. 术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[10]	王毅, 李红鹏, 张力月, 李庆云. 瘦素与重度哮喘的关联及机制研究进展[J]. 内科理论与实践, 2022, 17(01): 88-91.
[11]	朱秋艳, 薛岑. 半胱氨酸蛋白酶抑制剂C在呼吸系统疾病中的研究进展[J]. 内科理论与实践, 2022, 17(01): 102-106.
[12]	雷晓旭王春赵曦. 炎症微环境作用下ＢＭＰｓ－ＥＲＫ５信号通路对牙周膜干细胞成骨分化的影响 #br#[J]. 组织工程与重建外科杂志, 2021, 17(1): 30-.
[13]	宋娟, 邢寅, 黄慧, 陆帅, 秦利. 上海市崇明地区中老年人群血白细胞计数与血尿酸水平相关性研究[J]. 内科理论与实践, 2021, 16(06): 413-417.
[14]	施仲伟. 回眸过去30年全球和中国的心血管疾病负担及其危险因素——1990年至2019年全球心血管疾病负担及其危险因素报告解读[J]. 诊断学理论与实践, 2021, 20(04): 349-355.
[15]	吴昊, 白英, 邓可武. 心外膜脂肪组织与心血管疾病和代谢性疾病[J]. 内科理论与实践, 2021, 16(03): 208-211.